EGFR and non-small cell lung carcinoma: Han’s team (133) infused an increasing dose of EGFR-targeted CAR-T cells into patients with EGFR positivity (> 50% expression) and recurrent/refractory NSCLC in a phase I clinical study (NCT01869166).